echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Reding Pharmaceuticals and Cullinan Oncology on CLN-0...

    Reding Pharmaceuticals and Cullinan Oncology on CLN-0...

    • Last Update: 2021-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Reding Pharmaceuticals (NASDAQ: ZLAB; Hong Kong Stock Exchange: 9688) and Cullinan Oncology announced that they have reached an exclusive authorized partnership to advance the development, production and commercialization of CLN-081 in Greater China.
    Oncology is a biopharmaceutical company dedicated to developing transformative targeting and immunotherapy for cancer patients.
    under the terms of the agreement, Cullinan Pearl, a subsidiary of Cullinan Oncology, will receive an advance payment of $20 million and will be eligible for development, registration and sales-based milestone payments of up to $211 million.
    addition, Reding Pharmaceuticals will pay Cullinan royalties based on clN-081's annual net sales in Greater China, including Chinese mainland, Hong Kong, Macau and Taiwan.
    will be awarded exclusive rights to develop, manufacture and commercialize CLN-081 in Greater China. Dr. Ying Du, founder, chairman and CEO of
    Redding Pharmaceuticals, said, "This EGFR exon 20 insertion mutation (Ex20ins) targeted drug in collaboration with Cullinan has the potential to be the best-in-class drug, creating synergies with Reding Pharmaceuticals' existing lung cancer product pipelines and further strengthening our layout in this disease area."
    china has one of the highest rates of EGFR mutations in lung cancer, while non-small cell lung cancer with Ex20ins mutations still has a huge unsolvent demand.
    looking forward to working closely with Cullinan to bring new hope to these patients at an early time.
    , Chief Executive Officer of Cullinan Oncology, said: "Reding Pharmaceuticals is the ideal partner for clinical development and commercialization in Greater China and we are delighted to be working with them to develop CLN-081.
    EGFR inhibitors currently on the market have not yet been able to adequately solve the problem of exon 20 insertion mutations.
    believe that CLN-081, with its available effectiveness and safety data, can meet the huge untreated treatment needs of patients with this mutation.
    look forward to working with Reding to start the development of CLN-081 in China as soon as possible.
    " about CLN-081CLN-081 is an oral small molecule, the next generation of irreversible EGFR inhibitors, selectively targeting cells that express EGFR mutations.
    An ongoing phase 1/2a dose increment and expansion study is being evaluated twice a day in patients with EGFR Ex20ins mutated non-small cell lung cancer who have previously received platinum-containing chemotherapy or another approved standard therapy.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.